Responses
Regular and young investigator award abstracts
Clinical trials in progress
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
